Nova Satra Health provides private equity investment capital to companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.

Nova Satra also provides market expansion solutions to the biotechnology and natural health sectors, right across the dynamic and growing South East Asian region. Nova Satra Health has forged distribution and trading relationships with a number of emerging players in the alternative health sector, including 98alive, a groundbreaking natural health product, developed in conjunction with Australia’s Griffith University.